Lexeo Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
Lexeo Therapeutics, Inc. (LXEO) reported Other Comprehensive Income (Loss), Net of Tax of -$156.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- Lexeo Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$156.00K, a 480.49% decline year-over-year.
- Lexeo Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$330.00K, a 773.47% decline year-over-year.
- Lexeo Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $99.00K.
- Lexeo Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $102.00K.
- Lexeo Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was $291.00K.
- Lexeo Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was -$103.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$156.00K 10-Q · filed 2026-08-12 | -$486.00K 10-Q · filed 2026-08-12 | -$387.00K derived: sum of 3 quarters · filed 2026-08-12 | -$285.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$330.00K 10-Q · filed 2026-05-11 | -$231.00K derived: sum of 2 quarters · filed 2026-05-11 | -$129.00K derived: sum of 3 quarters · filed 2026-05-11 | -$88.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $201.00K derived: sum of 2 quarters · filed 2026-03-30 | $242.00K derived: sum of 3 quarters · filed 2026-08-12 | $291.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $102.00K 10-Q · filed 2025-11-05 | $143.00K derived: sum of 2 quarters · filed 2026-08-12 | $192.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $41.00K 10-Q · filed 2026-08-12 | $90.00K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $49.00K 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$103.00K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |